Sellas Life Sciences Receives Fast Track Designation From FDA For SLS009 For Treatment Of Relapsed/Refractory Peripheral T-cell Lymphomas

SELLAS Life Sciences Group Inc -0.99% Pre

SELLAS Life Sciences Group Inc





0.00% Pre

- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL); ORR in r/r PTCL Patients with Standard of Care is 25.8% -

- Fast Track Designation Accelerates SLS009's Path to U.S. FDA Submission for Treatment of r/r PTCL -

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via